CClinicalTrials.gg
Active, not recruitingNCT04744675Updated Sep 19, 2024

Peripheral Nerve Injections for CRPS

A Phase 2 interventional study of Triamcinolone Acetonide 40mg/mL and Saline Injection in Complex Regional Pain Syndromes, sponsored by Ottawa Hospital Research Institute. Active, not recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Ottawa Hospital Research Institute · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background Complex regional pain syndrome (CRPS) is characterized by intense pain, loss of function, and associated with motor, trophic, sudomotor, and/or vasomotor changes of the affected extremity. Upper extremity CRPS is seen frequently in electrodiagnostic, neurology, and musculoskeletal clinics and occurs in up to one-third of patients who have undergone common surgical procedures (i.e. carpal tunnel surgery). To date, there is a limited understanding of the underlying pathophysiology of CRPS. As a consequence, few effective treatment options are available.

Peripheral nerve blocks have proven to be successful in reducing pain for several musculoskeletal and neurologic conditions. Similarly, this procedure could be used to block somatic and autonomic sensory fibers which are thought to contribute to CRPS. In a small exploratory study, investigators found peripheral nerve blocks in the upper extremity (suprascapular and median nerves) were well-tolerated in patients with CRPS and resulted in a 56% and 37% pain reduction in the shoulder and hand 2 weeks after injection, respectively. While this is highly encouraging, large randomized placebo-controlled trials (RCTs) are necessary to demonstrate effectiveness and safety of nerve blocks for this population before it is accepted into clinical practice. This proposal is a phase II feasibility study that will test the critical elements necessary for performing such a RCT.

Methods The investigators will recruit participants (≥18 years old) from The Ottawa Hospital, Bruyère Continuing Care (Elisabeth Bruyère Hospital, St-Vincent Hospital), and Providence Care Hospital (Kingston, ON), meeting the well-established clinical Budapest criteria for upper extremity CRPS and having a visual analog scale (VAS) pain score of at least 40 mm (to avoid flooring effect). Participants will be block-randomized by the Ottawa Methods Centre to receive injections of either A) intervention (suprascapular, median, and ulnar nerves) with bupivacaine and triamcinolone acetonide, or B) placebo (saline). All participants will receive standard care for CRPS.

Primary outcomes will focus on crucial methodologic aspects for the future RCT, including: (1) level of recruitment, (2) rate of acceptance from eligible patients to the randomization procedure, (3) blinding efficacy, (4) degree of patient retention, (5) rate of data completion, and (6) rate of adverse events for both the placebo and intervention groups.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Able to provide signed and dated informed consent form
  2. Male or female, aged ≥18 years old
  3. Satisfy the Budapest Criteria for upper extremity CRPS
  4. A VAS score of at least 40 mm in the upper extremity to avoid flooring effect for injection-related pain reduction

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled hypertension (>180/110)
  2. Sepsis
  3. Bleeding diathesis
  4. Active cancer
  5. Brachial plexus injuries
  6. Neurological language deficits precluding participation
  7. Mini mental state examination score \< 23
  8. Acute mental illness (An acute mental illness is characterized by clinically significant symptoms of any metal health illness that requires immediate treatment. The physician making the recommendation to be part of the study. If the patient exhibits symptoms of any mental health illness that is not being treated by either the recommending physician or another member of the patient's care team the patient will not be recommended to participate in the study)
  9. Patients who are pregnant or breastfeeding
04

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment

    The intervention group will receive: 1. Suprascapular nerve block - 3 mL of 0.5% Bupivacaine and 1 mL of 40 mg/mL Kenalog 2. Median nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog 3. Ulnar nerve block - 3.5 mL of 0.5% Bupivacaine and 0.5 mL of 40 mg/mL Kenalog

    Drug: Triamcinolone Acetonide 40mg/mL · Drug: Bupivacaine

  • Placebo comparator
    Placebo

    Placebo The placebo group will receive: 1. Suprascapular nerve injection - 4 mL of normal saline 2. Median nerve injection - 4 mL of normal saline 3. Ulnar nerve injection - 4 mL of normal saline

    Drug: Saline Injection

Interventions

  • DrugTriamcinolone Acetonide 40mg/mL

    Triamcinolone acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intramuscular, intra-articular, and intrabursal injection.

    Also known as: Kenalog

  • DrugSaline Injection

    Saline is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body.

  • DrugBupivacaine

    Bupivacaine is an anesthetic that is commonly used as a local numbing agent, including intramuscular, intra-articular and intrabursal injections.

    Also known as: Marcaine

05

What researchers measure

Primary outcomes

  1. Recruitment

    Number of participants who are successfully recruit into the study.

    Time frame: Week -2

  2. Randomization

    Number of participants who accept being randomized into either the intervention or placebo treatment arms and receive the injection accordingly.

    Time frame: Week 0

  3. Blinding - Participant

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 0

  4. Blinding - Participant

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 2

  5. Blinding - Participant

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 6

  6. Blinding - Participant

    The participants will be asked which arm they believe they are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 12

  7. Blinding - Interventionist

    The interventionist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 0

  8. Blinding - Physiotherapist

    The physiotherapist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 2

  9. Blinding - Physiotherapist

    The physiotherapist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 6

  10. Blinding - Physiotherapist

    The physiotherapist will be asked which arm they believe the participant is are part of and this response will be compared to their actual group allocation. The level of agreement between the actual group allocation and the guess provided will be compared using Bang's blinding index, we will consider blinding effective if the index is between -0.2 and 0.2 (zero being perfect blinding).

    Time frame: Week 12

  11. Retention

    The percentage of participants who remained in the study for the entire duration of their planned involvement.

    Time frame: Week 12

  12. Data completion

    The percentage of participants who complete all of the study questionnaires

    Time frame: Week 12

  13. Rate of Adverse events

    We will track adverse events the participants experience

    Time frame: Week 12

Secondary outcomes

  1. Pain - Visual Analog Scale

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

    Time frame: Week -2

  2. Pain - Visual Analog Scale

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

    Time frame: Week 0 - Immediately before injection

  3. Pain - Visual Analog Scale

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

    Time frame: Week 0 - Immediately after injection

  4. Pain - Visual Analog Scale

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

    Time frame: Week 2

  5. Pain - Visual Analog Scale

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

    Time frame: Week 6

  6. Pain - Visual Analog Scale

    We will track the pain experienced by the participants on a visual analog scale. The lowest score is 0 the highest score is 10. A higher value indicates a higher amount of pain experienced by the participant

    Time frame: Week 12

  7. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

    Time frame: Week -2

  8. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

    Time frame: Week 0

  9. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

    Time frame: Week 2

  10. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

    Time frame: Week 6

  11. Pain - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 4 and the highest possible score is 30, and a higher score indicates a worse outcome.

    Time frame: Week 12

  12. Pain - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week -2

  13. Pain - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 0

  14. Pain - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 2

  15. Pain - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 6

  16. Pain - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 12

  17. Disease Severity - Complex Regional Pain Syndrome Severity Score

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

    Time frame: Week -2

  18. Disease Severity - Complex Regional Pain Syndrome Severity Score

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

    Time frame: Week 0

  19. Disease Severity - Complex Regional Pain Syndrome Severity Score

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

    Time frame: Week 2

  20. Disease Severity - Complex Regional Pain Syndrome Severity Score

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

    Time frame: Week 6

  21. Disease Severity - Complex Regional Pain Syndrome Severity Score

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 17, and a higher score indicates a worse outcome.

    Time frame: Week 12

  22. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

    Time frame: Week -2

  23. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

    Time frame: Week 0

  24. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

    Time frame: Week 2

  25. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

    Time frame: Week 6

  26. Function - Disabilities of the Arm, Shoulder, and Hand Questionnaire

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 0 and the highest possible score is 100, and a higher score indicates a worse outcome.

    Time frame: Week 12

  27. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

    Time frame: Week -2

  28. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

    Time frame: Week 0

  29. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

    Time frame: Week 2

  30. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

    Time frame: Week 6

  31. Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 8 and the highest possible score is 40, and a higher score indicates a better outcome.

    Time frame: Week 12

  32. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

    Time frame: Week -2

  33. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

    Time frame: Week 0

  34. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

    Time frame: Week 2

  35. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

    Time frame: Week 6

  36. Emotional and Psychological Function - Patient-Reported Outcomes Measurement Information System 29 Profile V2

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 16 and the highest possible score is 80, and a higher score indicates a worse outcome.

    Time frame: Week 12

  37. Emotional and Psychological Function - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week -2

  38. Emotional and Psychological Function - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 0

  39. Emotional and Psychological Function - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 2

  40. Emotional and Psychological Function - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 6

  41. Emotional and Psychological Function - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 12

  42. Quality of Life - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week -2

  43. Quality of Life - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 0

  44. Quality of Life - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 2

  45. Quality of Life - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 6

  46. Quality of Life - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 1 and the highest possible score is 5, and a higher score indicates a worse outcome.

    Time frame: Week 12

  47. Total Score - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

    Time frame: Week -2

  48. Total Score - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

    Time frame: Week 0

  49. Total Score - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

    Time frame: Week 2

  50. Total Score - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

    Time frame: Week 6

  51. Total Score - EQ-5D-5L

    These outcomes will allow us to better understand the holistic effect of the intervention. The lowest possible score is 5 and the highest possible score is 25, and a higher score indicates a worse outcome.

    Time frame: Week 12

06

Study locations

2 sites
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Elisabeth Bruyere Hospital
    Ottawa, Ontario K1N5C8, Canada
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04744675
Lead sponsor
Ottawa Hospital Research Institute
Responsible party
Sponsor
First posted
Feb 9, 2021
Start date
May 30, 2024
Primary completion
Jul 30, 2024
Completion
Jun 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Mark Campbell, MD
principal investigator · Elisabeth Bruyere Hospital and The Ottawa Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion